Scott Beegle, MD
Internal Medicine · Albany, NYNPI 1437159837
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,617,539 of the $1,884,609 with a category attached, or 85.8%. 29 manufacturers reported payments, led by GSK at 29.3% of the total. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,255 payments — averaging $835.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$553K
- Sanofi$393K
- Regeneron Healthcare Solutions, Inc.$226K
- AstraZeneca$151K
- Boehringer Ingelheim$122K
- CSL Behring$82K
- plus $358K from 23 others
Across 55 payments — averaging $3065.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Redhill Biopharma Inc.$61K
- Genentech, Inc.$54K
- Boehringer Ingelheim$53K
- GSK$344
- Janssen Research & Development, LLC$12
What the payments were for
- Consulting fees$99,7235%
- Speaking & faculty fees$1,617,53986%
- Travel & lodging$104,7486%
- Food & beverage$60,4213%
- Education$2,1610%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 583 | $553,050 |
| Sanofi | 358 | $392,947 |
| Regeneron Healthcare Solutions, Inc. | 270 | $226,169 |
| AstraZeneca(2 entities) | 240 | $150,638 |
| Boehringer Ingelheim | 153 | $121,627 |
| CSL Behring | 115 | $81,748 |
| Johnson & Johnson | 79 | $63,053 |
| Genentech USA, Inc. | 91 | $57,822 |
| Amgen | 73 | $51,861 |
| Insmed, Inc. | 72 | $41,302 |
| Astellas Pharma US Inc | 59 | $38,728 |
| Shionogi Inc | 35 | $33,494 |
| Merck | 44 | $22,463 |
| Sunovion Pharmaceuticals Inc. | 29 | $15,395 |
| Mylan Specialty L.p. | 11 | $8,853 |
| Novartis | 11 | $7,573 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,111 |
| Verona Pharma, Inc. | 4 | $3,780 |
| United Therapeutics Corporation | 4 | $2,202 |
| Pfizer | 4 | $2,031 |
| Nabriva Therapeutics, PLC | 2 | $1,784 |
| Teva Pharmaceuticals USA, Inc. | 1 | $1,680 |
| Viiv Healthcare Company | 1 | $1,600 |
| Genentech, Inc. | 8 | $434 |
| Mallinckrodt Hospital Products Inc. | 1 | $123 |
| Zambon USA Ltd. | 1 | $54 |
| Electromed, Inc. | 1 | $37 |
| Grifols USA, LLC | 1 | $27 |
| Teleflex LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$589,776
- NUCALA$284,322
- TRELEGY ELLIPTA$155,269
- TEZSPIRE$91,648
- Kcentra$80,112
- XARELTO$61,652
- OFEV$40,367
- Tavneos$35,825
- FASENRA$33,987
- Esbriet$32,661
- Fetroja$29,130
- CRESEMBA$28,134
- XOLAIR$25,913
- AREXVY$25,621
- Arikayce$20,464
- ZERBAXA$18,351
- LONHALA MAGNAIR$14,798
- ANORO ELLIPTA$14,633
- ULTOMIRIS$7,392
- Yupelri$4,593
How this compares
$1,884,609 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 33 | $413,967 |
| Tyvaso DpiTreprostinil | 12 | $285,742 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $213,279 |
| NucalaMepolizumab | 23 | $165,519 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 108 | $130,241 |
| Dupixent PenDupilumab | 19 | $100,175 |
| Ambrisentan | 13 | $29,734 |
| EliquisApixaban | 30 | $28,570 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $24,521 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $24,187 |
| Spiriva RespimatTiotropium Bromide | 12 | $11,114 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $5,542 |
| Bosentan | 11 | $4,606 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,505 |
| Buprenorphine | 11 | $4,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $121,627 | $425,08045 claims |
| GSKNucala, Trelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $553,050 | $348,974207 claims |
| Grifols USA, LLCProlastin C | $27 | $213,27912 claims |
| PfizerEliquis | $2,031 | $28,57030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Albany
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.